Cody J Wenthur
Elucidating how monoaminergic and glutamatergic signaling systems interact to support maladaptive learning and synaptic plasticity in the context of substance use disorders and major depressive disorders; Development of novel bioconjugates and antibodies to probe the effects of psychoactive substances, including synthetic cannabinoids, opioids, ketamine, and classical psychedelics; Identifying immunologic biomarkers of ongoing drug use and vaccine response; Assessing barriers to implementation of novel addiction treatment paradigms, including vaccine-based approaches and medication-assisted psychotherapy
|Aug 2018 - Present||Assistant Professor
University of Wisconsin–Madison – Pharmacy Practice Division
and Pharmaceutical Sciences Division
|Aug 2015- July 2018||Postdoctoral Research Fellow
The Scripps Research Institute, La Jolla – Department of Chemistry
|Aug 2011 - Aug 2015||Doctor of Philosophy - Pharmacology
Vanderbilt University – School of Medicine
|Aug 2005 - May 2011||Doctor of Pharmacy
Purdue University – College of Pharmacy
Wenthur CJ, Gautam R, Zhou B, Vendruscolo LF, Leggio L, Janda KD. Ghrelin Receptor Influence on Cocaine Reward is Not Directly Dependent on Peripheral Acyl-Ghrelin. Scientific Reports, 9 (1): 1841. 2019.
Wenthur CJ, Zhao B, Janda KD. Vaccine-driven pharmacologic dissection and mitigation of fenethylline psychoactivity. Nature, 548; (7668):476-479. 2017.
Kimishima A, Wenthur CJ, Zhou B, Janda KD. An advance in prescription opioid vaccines: Overdose mortality reduction and extraordinary alteration of drug half-life. ACS Chemical Biology. 12; (1):36-40. 2017.
Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Lindsley CW, Conn PJ. Metabotropic glutamate receptor 3 (mGlu3) activation is required for group II mGlu long-term depression in the medial prefrontal cortex and fear extinction learning. Proceedings of the National Academy of Sciences USA. 112; (4):1196-201. 2015.
Wenthur CJ, Morrison R, Felts AS, Smith KA, Engers JL, Byers FW, Daniels JS, Emmitte KA, Conn PJ, Lindsley CW. Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM). Journal of Medicinal Chemistry 56; (12):5208-12. 2013.
Wenthur CJ, Romack BS, Vernon VP, Shelly JL, Harth BN, Lienhoop AD, Madison NR, Murawski MM. Opinions and experiences of Indiana pharmacists and student pharmacists: The need for substance abuse education. Research in Social and Administrative Pharmacy 9; (1):90-100. 2013.